Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. (Q51831972)
Jump to navigation
Jump to search
scientific article published on 15 November 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. |
scientific article published on 15 November 2005 |
Statements
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. (English)
1 reference
T Lissitchkov
1 reference
G Arnaudov
1 reference
D Peytchev
1 reference
Kh Merkle
1 reference
15 November 2005
1 reference
132
1 reference
2
1 reference
99-104
1 reference
1 reference
1 reference
1 reference
1 reference